AIM Competitors

Stocks . USA . 
Stock . AIM ImmunoTech
AIM Stock  USD 1.12  0.07  5.88%   
AIM ImmunoTech competes with Kala Pharmaceuticals, Oragenics, Pasithea Therapeutics, Vyne Therapeutics, and Quoin Pharmaceuticals; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing AIM ImmunoTech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of AIM ImmunoTech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out AIM ImmunoTech Correlation with its peers.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.

AIM ImmunoTech vs Soligenix Correlation

Very weak diversification

The correlation between AIM ImmunoTech and SNGX is 0.59 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding AIM ImmunoTech and SNGX in the same portfolio, assuming nothing else is changed.

Moving against AIM Stock

  0.696C1 CytomX TherapeuticsPairCorr
  0.62DRTS Alpha Tau MedicalPairCorr
  0.538VP1 AVRICORE HEALTH INCPairCorr
  0.49GXEA Galapagos NV Earnings Call This WeekPairCorr
  0.49CMB Cambium Bio Earnings Call This WeekPairCorr
At this time, AIM ImmunoTech's Return On Capital Employed is very stable compared to the past year. As of the 19th of February 2026, Return On Equity is likely to grow to 12.38, though Return On Tangible Assets are likely to grow to (3.15). At this time, AIM ImmunoTech's Non Current Assets Total are very stable compared to the past year. As of the 19th of February 2026, Intangible Assets is likely to grow to about 3.1 M, while Other Current Assets are likely to drop about 217.4 K.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.061.1511.06
Details
Intrinsic
Valuation
LowRealHigh
0.224.3214.23
Details
Naive
Forecast
LowNextHigh
0.021.2511.15
Details
2 Analysts
Consensus
LowTargetHigh
12.7313.9915.52
Details

AIM ImmunoTech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between AIM ImmunoTech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of AIM and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of AIM ImmunoTech does not affect the price movement of the other competitor.

High positive correlations

SNGX
+ 0.87
ENSC
ENSC
+ 0.84
QNRX
ENSC
+ 0.83
KALA
CANF
+ 0.82
ENSC
SNGX
+ 0.79
KALA
SNGX
+ 0.79
OGEN
  

High negative correlations

CANF
- 0.88
VYNE
ENSC
- 0.81
VYNE
SNGX
- 0.71
VYNE
VYNE
- 0.68
KALA
QNRX
- 0.6
VYNE
TCRT
- 0.57
VYNE

Risk-Adjusted Indicators

There is a big difference between AIM Stock performing well and AIM ImmunoTech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze AIM ImmunoTech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
KALA  6.73 (0.23) 0.00 (0.58) 0.00 
 0.00 
 13.33 
(11.32)
 59.48 
OGEN  3.84 (0.42) 0.00 (0.18) 0.00 
 0.00 
 7.69 
(7.69)
 24.70 
KTTA  8.02  2.83  0.48  3.89  4.07 
(13.04)
 23.54 
(7.75)
 137.41 
VYNE  3.00  1.10  0.28 (3.85) 1.98 
(5.38)
 5.56 
(5.08)
 55.08 
QNRX  6.07 (0.64) 0.00  0.65  0.00 
 0.00 
 13.83 
(10.99)
 49.90 
ENSC  5.47 (2.09) 0.00 (1.68) 0.00 
 0.00 
 10.64 
(12.59)
 60.48 
XTLB  5.26  0.64  0.08 (2.87) 5.95 
(6.48)
 8.25 
(10.53)
 69.50 
TCRT  4.22 (0.29) 0.00 (0.09) 0.00 
 0.00 
 9.61 
(9.52)
 24.31 
CANF  5.15 (0.08) 0.00  0.09  0.00 
 0.00 
 10.40 
(7.94)
 38.42 
SNGX  3.42 (0.36) 0.00 (0.22) 0.00 
 0.00 
 5.97 
(6.25)
 27.24 

AIM ImmunoTech Competitive Analysis

The better you understand AIM ImmunoTech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, AIM ImmunoTech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across AIM ImmunoTech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AIM KALA OGEN KTTA VYNE QNRX ENSC XTLB TCRT CANF
 5.88 
 1.12 
AIM
 5.26 
 0.40 
Kala
 12.50 
 0.72 
Oragenics
 14.29 
 0.80 
Pasithea
 1.69 
 0.60 
Vyne
 0.95 
 9.38 
Quoin
 2.56 
 0.40 
Ensysce
 5.95 
 0.89 
XTL
 0.78 
 2.60 
Alaunos
 3.02 
 4.44 
Can
Market Volatility
(90 Days Market Risk)
Very risky
Out of control
Extremely Dangerous
Out of control
Abnormally volatile
Slightly risky
Very risky
Out of control
Dangerous
Very risky
Market Performance
(90 Days Performance)
Weak
Weakest
Weakest
Good
Good
Weakest
Weakest
Mild
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Risky
Small
Small
Moderate
Risky
Risky
Low
High
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
14.21
2.54
12.31
51.17
7.6
0.96
0.87
31.26
2.29
6.78
Net Asset
8.61 M
55.48 M
1.47 M
16.06 M
66.91 M
15.71 M
5.6 M
8.55 M
2.75 M
9.12 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
-2.44
N/A
N/A
N/A
EBITDA
(16.49 M)
(40.98 M)
(10.54 M)
(13.6 M)
(43.63 M)
(9.43 M)
(6.73 M)
(930 K)
(4.68 M)
(8.12 M)
Operating Margin
-94.12
N/A
N/A
N/A
-46.11
N/A
-7.59
-8.54
-678.83
-24.25
Current Valuation
4.18 M
379.3 M
(8.27 M)
4.42 M
(20.65 M)
9.21 M
294.53 K
8.47 M
(80.7 K)
(641.14 K)
Price To Book
2.72
8.34
0.28
1.34
0.6
1.68
1.3
1.9
2.13
1.42
Retained Earnings
(426.83 M)
(667.92 M)
(216.79 M)
(49.58 M)
(731.17 M)
(55.17 M)
(129.54 M)
(159.01 M)
(920.45 M)
(166.36 M)
Current Asset
15.73 M
84.65 M
5.64 M
N/A
N/A
N/A
N/A
3 M
N/A
39.51 M
Beta
1.24
-2.44
1.11
0.21
2.03
1.87
1.15
0.81
-1.25
0.042
Number Of Employees
21
38
3
4
13
3
7
10
1
5
Shares Outstanding
3.4 M
911.33 M
4.17 M
22.4 M
33.29 M
1.62 M
3.63 M
9.46 M
2.23 M
17.07 M
Cash Flow From Operations
(14.89 M)
(29.38 M)
(8.6 M)
(13.92 M)
(33.97 M)
(7.86 M)
(7.5 T)
(1.62 M)
(4.97 M)
(7.64 M)
Total Debt
2.94 M
32.25 M
328.53 K
1.28 M
99 K
6.5 M
301.66 K
138 K
692 K
104 K
Return On Equity
-31.39
-7.08
-1.69
-0.9
-0.71
-6.51
-2.94
-5.77
-1.46
-2.64
Return On Asset
-0.95
-0.66
-0.71
-0.54
-0.42
-0.99
-1.1
-2.41
-0.7
-0.82
Number Of Shares Shorted
328.27 K
580.62 K
524.16 K
264.67 K
544.78 K
27.83 K
201.25 K
212.09 K
44.6 K
51.4 K
Book Value Per Share
-2.2
-1.17
2.38
1.64
1.01
-2.06
0.38
N/A
1.27
0.001
Current Liabilities
6.65 M
10.53 M
1.05 M
N/A
N/A
N/A
N/A
N/A
N/A
5.77 M
Total Asset
8.61 M
55.48 M
1.47 M
16.06 M
66.91 M
15.71 M
5.6 M
8.55 M
2.75 M
9.12 M
Debt To Equity
0.02
4.77
0.023
0.008
N/A
0.47
6.91
N/A
0.69
0.008
Short Ratio
1.78
0.29
0.62
0.21
0.95
0.72
1.64
0.11
1.49
0.19
Target Price
13.99
1.5
2.0
3.0
2.0
40.67
16.45
30.0
1.75
3.5
Shares Owned By Institutions
4.89
24.81
6.88
22.9
21.18
57.2
12.42
2.66
6.36
5.53
Market Capitalization
4.05 M
362.71 M
3 M
25.09 M
19.75 M
14.48 M
1.58 M
7.95 M
5.76 M
15.24 M
Price To Earning
12.5
-0.52
-2.28
N/A
N/A
N/A
N/A
4.5
N/A
-3.41
Price To Earnings To Growth
-0.04
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
36.16
1.16
89.28
42.15
37.7
N/A
0.35
8.21
959.69
10.08
Net Income
(17.32 M)
(38.51 M)
(10.57 M)
(13.9 M)
(39.83 M)
(9.01 M)
(7.99 M)
(1.03 M)
(4.68 M)
(7.88 M)
Earnings Per Share
-18.16
-5.64
48.21
-4.43
-0.79
-29.17
-6.35
-0.9
-2.3
N/A
Shares Owned By Insiders
3.85
0.23
2.38
1.52
4.31
3.5
0.29
38.46
4.37
N/A
Revenue
170 K
N/A
N/A
N/A
501 K
N/A
5.21 M
451 K
10 K
674 K
Working Capital
(5.36 M)
35.84 M
(211.88 K)
6.25 M
49.62 M
10.75 M
3.14 M
(867 K)
2.06 M
6.93 M
Cash And Equivalents
1.7 M
44.57 M
17.87 M
47.94 M
42.81 M
2.69 M
3.15 M
5.16 M
60.01 M
12.77 M
Cash Per Share
0.76
30.44
0.15
1.8
0.74
0.56
0.1
0.95
0.28
0.47
Gross Profit
17 K
1.33 M
(3.39 M)
(2.21 K)
524 K
N/A
(6.08 M)
(2.25 M)
(910 K)
560 K
Day Typical Price
1.15
0.4
0.69
0.81
0.59
9.38
0.38
0.88
2.59
4.39
Accumulation Distribution
5874.79
12381.29
0.12
96679.0
14539.45
152.11
83797.25
1943.91
747.75
427.21
Market Facilitation Index
0.0
N/A
0.09
N/A
N/A
0.0
N/A
0.0
0.0
0.0
Daily Balance Of Power
(0.58)
0.6667
0.8889
0.5556
0.3333
(0.38)
0.2
0.5
0.1176
0.8125
Period Momentum Indicator
(0.07)
0.02
0.08
0.1
0.01
(0.09)
0.01
0.05
0.02
0.13
Rate Of Daily Change
0.94
1.05
1.13
1.14
1.02
0.99
1.03
1.06
1.01
1.03
Day Median Price
1.16
0.41
0.68
0.81
0.59
9.38
0.38
0.87
2.59
4.36
Price Action Indicator
(0.07)
0.005
0.085
0.04
0.02
(0.04)
0.03
0.045
0.025
0.15
Relative Strength Index
38.24
37.92
40.51
36.52
56.1
19.76
25.97
46.32
37.48
43.58
Coefficient Of Variation
(34,664)
(5,143)
(1,583)
619.22
641.6
(1,295)
(405.88)
1537.25
(3,283)
(3,874)
Mean Deviation
5.44
6.73
3.84
8.02
3.0
6.07
5.47
5.26
4.22
5.15
Jensen Alpha
(0.12)
(0.23)
(0.42)
2.83
1.1
(0.64)
(2.09)
0.6368
(0.29)
(0.08)
Total Risk Alpha
(0.70)
(0.92)
(0.68)
1.62
0.5947
(1.33)
(2.60)
(0.06)
(0.57)
(0.71)
Sortino Ratio
N/A
N/A
N/A
0.4784
0.2786
N/A
N/A
0.0824
N/A
N/A
Downside Variance
N/A
N/A
N/A
34.71
13.74
N/A
N/A
48.11
N/A
N/A
Standard Deviation
9.48
10.13
5.03
17.85
7.03
8.95
8.19
9.76
5.6
7.27
Kurtosis
21.68
6.72
0.7232
28.67
40.86
4.57
5.8
19.71
0.0029
2.62
Potential Upside
10.14
13.33
7.69
23.54
5.56
13.83
10.64
8.25
9.61
10.4
Treynor Ratio
(0.03)
(0.58)
(0.18)
3.89
(3.85)
0.6549
(1.68)
(2.87)
(0.09)
0.0906
Maximum Drawdown
66.23
59.48
24.7
137.41
55.08
49.9
60.48
69.5
24.31
38.42
Variance
89.8
102.64
25.26
318.55
49.47
80.17
67.09
95.31
31.39
52.92
Market Risk Adjusted Performance
(0.02)
(0.57)
(0.17)
3.9
(3.84)
0.6649
(1.67)
(2.86)
(0.08)
0.1006
Risk Adjusted Performance
0.007
(0.01)
(0.04)
0.1333
0.1283
(0.05)
(0.18)
0.0591
(0.01)
(0.01)
Skewness
3.66
2.04
0.2746
4.89
5.87
(0.30)
0.7026
3.55
0.2306
(0.30)
Semi Deviation
N/A
N/A
N/A
4.07
1.98
N/A
N/A
5.95
N/A
N/A
Information Ratio
(0.01)
(0.03)
(0.08)
0.1579
0.1468
(0.08)
(0.25)
0.0585
(0.04)
(0.03)
Value At Risk
(10.32)
(11.32)
(7.69)
(7.75)
(5.08)
(10.99)
(12.59)
(10.53)
(9.52)
(7.94)
Expected Short fall
N/A
N/A
N/A
(13.04)
(5.38)
N/A
N/A
(6.48)
N/A
N/A
Downside Deviation
N/A
N/A
N/A
5.89
3.71
N/A
N/A
6.94
N/A
N/A
Semi Variance
N/A
N/A
N/A
16.56
3.94
N/A
N/A
35.43
N/A
N/A

AIM ImmunoTech Competition Performance Charts

Five steps to successful analysis of AIM ImmunoTech Competition

AIM ImmunoTech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by AIM ImmunoTech in relation to its competition. AIM ImmunoTech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of AIM ImmunoTech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact AIM ImmunoTech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to AIM ImmunoTech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your AIM ImmunoTech position

In addition to having AIM ImmunoTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Rentals Thematic Idea Now

Rentals
Rentals Theme
Companies providing rental and leasing services to public and business. The Rentals theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rentals Theme or any other thematic opportunities.
View All  Next Launch
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
How To Invest In AIM
Details
Is AIM Stock a good investment?
Details
What is AIM ImmunoTech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out AIM ImmunoTech Correlation with its peers.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(18.16)
Revenue Per Share
0.106
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.95)
Return On Equity
(31.39)
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY